An interventional study of GFAP/D-Dimer Point-of-Care Testing & CEREBO Near-Infrared Spectroscopy (NIRS) and CT Head in Stroke, sponsored by Christian Medical College and Hospital, Ludhiana, India. Not yet recruiting at 2 sites in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Christian Medical College and Hospital, Ludhiana, India · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Stroke with a site in India — 6 open to participants now, 9 under way, 4 of them phase 3. Stroke · India.
Among the 70 studies in Stroke with a site in India, this one is the 34th largest by planned enrollment of the 63 interventional ones that give a count, is the only one that started in 2027, is one of 19 with no phase, and was the 70th registered.
8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
Browse Stroke studies →6 of the 70 studies in Stroke with a site in India are open now. Recruiting first, the newest first:
Christian Medical College and Hospital, Ludhiana, India · Sites in India
Ages 18–99
Eli Lilly and Company · Sites in India, Argentina, Australia and 35 more countries
Ages 50+
Christian Medical College and Hospital, Ludhiana, India · Sites in India
Ages 18–99
Population Health Research Institute · Sites in India, United States, Argentina and 15 more countries
Ages 55+
Christian Medical College and Hospital, Ludhiana, India · Sites in India
Ages 18–99
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 24 · Phase 4 6
First in 1998; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 232 is above the median of 48 across 6,037 interventional studies indexed under Stroke.
Median enrollment 317 across the 63 interventional studies, 1,116 across the 7 observational. Of the 56 that completed or were terminated, 17 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 70 have an industry lead sponsor. The 10 most frequent:
Christian Medical College and Hospital, Ludhiana, India is the lead sponsor of 12 studies on the registry; 5 are open to participants now.
Christian Medical College and Hospital, Ludhiana, India has 8 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
2 of the studies in Stroke with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05836831Christian Medical College and Hospital, Ludhiana, IndiaIndian Trial of Tranexamic Acid in Spontaneous Intracerebral Haemorrhage | 2026-11 |
| NCT05955326Pharmazz, Inc.Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2026-12-18 |
Add all 2 to your calendar (.ics) → With an account.
Among the 70 studies in Stroke with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
CEREBO is an ICMR award winning point-of-care (POC) adjunct CT scanning device for detecting brain hematomas in patients with head injury. The study aims to validate the diagnostic accuracy of the PREDICT Assessment Model (CEREBO-NIRS plus GFAP/D-Dimer POC Assay) in patients with suspected stroke. The study will be conducted as part of the Indian Council of Medical Research's National Health Research Priority (ICMR-NHRP) under the INDIA-EMS project using a two phase design.
PHASE I: Validation of a diagnostic accuracy and feasbility of PREDICT assessment model (a combined approach using GFAP/ D-dimer POC lateral flow assay plus CEREBO-NIRS technology).
Study Design: Prospective, Multicenter, Validation and Feasibility Study.
PHASE II: Pilot RCT to assess integration of the PREDICT assessment model into pre-hospital pathways.
Study Design: Pilot Randomized Controlled Trial (RCT) (Year 3-5)
This study, titled "Prehospital Rapid Evaluation and Detection in Cerebrovascular Triage: A Multicenter Study of Glial Fibrillary Acidic Protein Point-of-Care Testing and Handheld Near-Infrared Spectroscopy Technology (CEREBO) in India," aims to validate the PREDICT Assessment Model, which combines GFAP/D-Dimer point-of-care testing with handheld CEREBO Near-Infrared Spectroscopy (NIRS) technology for the rapid differentiation of ischemic stroke and intracerebral hemorrhage in the prehospital setting.
The study will be conducted under the Indian Council of Medical Research (ICMR) National Health Research Priority (NHRP) programme as part of the INDIA-EMS project and will use a two-phase design. Phase I is a prospective, multicenter validation and feasibility study involving patients with suspected acute stroke presenting by ambulance or directly to the emergency department. Participants will undergo clinical assessment, including BE-FAST and neurological assessment, finger-prick blood testing for GFAP/D-Dimer, and CEREBO-NIRS assessment. All participants will subsequently undergo standard diagnostic evaluation with a CT head scan, which will serve as the gold standard for stroke subtype classification. The diagnostic accuracy, feasibility, process times, and safety of the combined PREDICT Assessment Model will be evaluated.
Phase II will be a pilot randomized controlled trial evaluating the integration of the PREDICT Assessment Model into prehospital stroke pathways. Ambulance services within the catchment areas of CMC Ludhiana and JIPMER Puducherry will be randomized to intervention or control groups. In the intervention group, ambulance personnel will use GFAP/D-Dimer testing and CEREBO-NIRS technology to support prehospital stroke classification and triage, in coordination with the on-call stroke team. The control group will receive standard care, including transport to the hospital for CT-based diagnosis and subsequent treatment decisions.
The primary objective of the study is to validate the diagnostic accuracy and feasibility of the combined GFAP/D-Dimer and CEREBO-NIRS approach and to assess its potential impact on prehospital stroke triage. Phase II will additionally assess the effect of the intervention on the time from ambulance dispatch to initiation of stroke-specific treatment. Secondary outcomes include functional outcome at 90 days measured by the modified Rankin Scale, in-hospital mortality, and adverse events.
Phase 1
Inclusion criteria
Exclusion criteria:
Phase 2
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ambulances in the intervention group will use the GFAP/D-Dimer point-of-care test and CEREBO Near-Infrared Spectroscopy (NIRS) technology to classify suspected acute stroke in the prehospital setting. Patients suspected of ischemic stroke and large vessel occlusion will be rapidly triaged to a comprehensive stroke centre, while patients suspected of intracerebral hemorrhage will receive stringent blood pressure control in the ambulance according to established protocols. Decision-making will be undertaken in conjunction with the on-call stroke team through the PREDICT App.
Diagnostic Test: GFAP/D-Dimer Point-of-Care Testing & CEREBO Near-Infrared Spectroscopy (NIRS)
Ambulances in the control group will follow standard care procedures, including rapid transport of patients to the hospital for CT head imaging, followed by treatment decisions based on the CT findings.
Diagnostic Test: CT Head
A finger-prick blood sample will be obtained from patients with suspected acute stroke and tested using a GFAP/D-Dimer lateral flow assay. The test will provide rapid biomarker results to support differentiation between ischemic stroke and intracerebral hemorrhage in the prehospital setting and The handheld CEREBO-NIRS device will be applied non-invasively to the patient's scalp to detect intracranial hematoma by assessing asymmetry in near-infrared optical density. The findings will be recorded and used as part of the PREDICT Assessment Model for stroke subtype classification.
Standard care CT head imaging
PREDICT assessment model
(Phase 1) Sensitivity and Specificity and PREDICT assessment model. Accurate identification of ICH \>90% using PREDICT model.
Time frame: 30 mins
Time for Device Application by Paramedics
(Phase 1) The time taken by paramedics/ ED personnel to apply the CEREBO NIRS device and obtain GFAP/D Dimer results. Lesser time indicates good outcome.
Time frame: 30 mins
Treatment initiation
(Phase 2) Time from Ambulance dispatch to initiation of stroke-specific treatment (Triage to Stroke ready centre or rapid BP control). Lesser time indicates better outcome.
Time frame: 30 mins
Inter-Center Variability
(Phase 1) Comparison of diagnostic accuracy and feasibility metrics between CMC Ludhiana and JIPMER Puducherry to assess consistency across centres. More consistency indicates good outcome.
Time frame: 2 years
Correlation with Gold Standard
(Phase 1) Agreement between the PREDICT assessment model and the CT head scan diagnosis (the gold standard). More correlation indicates better outcome.
Time frame: 2 years
Safety Metrics
Phase 1 Documentation of adverse events related to the testing procedure. Fewer events indicate a better outcome.
Time frame: 2 years
modified Rankin Scale
Phase 2 Functional outcome at 90 days Lower score (0-3) indicates good outcome
Time frame: 90 days
In-hospital mortality
Phase 2 In-hospital mortality. Lesser mortality indicates better outcome
Time frame: 7 days
Adverse events
Phase 2 Incidence of adverse events (e.g., symptomatic ICH). Lesser events indicate better outcome.
Time frame: 90 days
Plan to share: No — The study protocol does not currently specify a plan for sharing individual participant data (IPD) with other researchers. Any future IPD sharing will be considered in accordance with applicable ethical, regulatory, and data-protection requirements.
Start is estimated for Sep 2027; primary completion for Aug 2031, 47 months later.
Of 3,119 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 47 months is above that.
Counting every sponsor, half of 3,263 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Christian Medical College and Hospital, Ludhiana, India